Insulet Co. (NASDAQ:PODD) Shares Sold by Ithaka Group LLC

Ithaka Group LLC lowered its holdings in Insulet Co. (NASDAQ:PODD) by 1.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,821 shares of the medical instruments supplier’s stock after selling 468 shares during the quarter. Insulet accounts for about 1.3% of Ithaka Group LLC’s holdings, making the stock its 26th biggest position. Ithaka Group LLC’s holdings in Insulet were worth $6,941,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PODD. Blue Trust Inc. lifted its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Insulet during the 2nd quarter worth $32,000. Venturi Wealth Management LLC raised its stake in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its stake in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the last quarter.

Insulet Stock Down 1.3 %

PODD opened at $262.99 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.45 billion, a price-to-earnings ratio of 45.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22. The business has a 50-day moving average of $240.74 and a two-hundred day moving average of $209.99. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40.

Analyst Upgrades and Downgrades

PODD has been the subject of several research reports. Raymond James lifted their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler lifted their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. UBS Group lifted their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Finally, Canaccord Genuity Group lifted their price objective on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.